Cours suspendu

Autres langues Eiger BioPharmaceuticals

Actions

EIGR

US28249U2042

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets Autres places de cotation 17:27:07 27/09/2024			Varia. 5j.	Varia. 1 janv.
8,500 ^USD	-.--%		-.--%	-

01/10/24	Eiger BioPharmaceuticals se place sous la protection du chapitre 11 de la loi sur les faillites et le plan de liquidation prend effet	CI
30/09/24	Eiger BioPharmaceuticals, Inc. a cessé ses activités	CI

Autres langues

01/10/24	Eiger BioPharmaceuticals Files for Chapter 11 Bankruptcy as Liquidation Plan Takes Effect
01/10/24	Eiger BioPharmaceuticals : DEBTOR AFFILIATES PURSUANT TO CHAPTER 11 OF THE BANKRUPTCY CODE Form 8 K
30/09/24	Eiger BioPharmaceuticals, Inc. Went Out of Business
05/09/24	Combined Hearing for Disclosure Statement and Plan Approved for Eiger BioPharmaceuticals, Inc.
05/09/24	Fifth Amended Joint Liquidation Plan Filed by Eiger BioPharmaceuticals, Inc.
04/09/24	First Motion for Exclusivity Period Extension Approved For Eiger BioPharmaceuticals, Inc.
03/09/24	Fourth Amended Joint Liquidation Plan Filed by Eiger BioPharmaceuticals, Inc.
03/09/24	Eiger InnoTherapeutics, Inc. acquired Peginterferon Lambda Assets from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $1 million.
03/09/24	Eiger InnoTherapeutics, Inc. acquired Peginterferon Lambda Assets from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $1 million.
03/09/24	Eiger InnoTherapeutics, Inc. completed the acquisition of Lonafarnib Antiviral Asset of Eiger BioPharmaceuticals, Inc. from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $5.2 million.
28/08/24	Third Amended Joint Liquidation Plan & Disclosure Statement Filed by Eiger BioPharmaceuticals, Inc.
21/08/24	Motion for Asset Sale Approved for Eiger BioPharmaceuticals, Inc.
15/08/24	Second Amended Joint Liquidation Plan & Disclosure Statement Filed by Eiger BioPharmaceuticals, Inc.
05/08/24	Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc.
02/08/24	Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc.
02/08/24	Eiger InnoTherapeutics, Inc. agreed to acquire Lonafarnib Antiviral Asset of Eiger BioPharmaceuticals, Inc. from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $5.2 million.
01/08/24	Eiger InnoTherapeutics, Inc. entered into Peginterferon Lambda Asset Purchase Agreement to acquire Peginterferon Lambda Assets from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $1 million.
01/08/24	Eiger InnoTherapeutics, Inc. entered into Peginterferon Lambda Asset Purchase Agreement to acquire Peginterferon Lambda Assets from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $1 million.
30/07/24	Disclosure Statement Conditionally Approved for Eiger BioPharmaceuticals, Inc.
28/07/24	First Amended Joint Liquidation Plan & Disclosure Statement Filed by Eiger BioPharmaceuticals, Inc.
23/07/24	First Motion for Exclusivity Period Extension Filed by Eiger BioPharmaceuticals, Inc.
16/07/24	Eiger BioPharmaceuticals : THIS IS NOT A SOLICITATION OF ACCEPTANCE OR REJECTION OF THE PLAN. THE DEBTORS ARE SEEKING APPROVAL OF THE DISCLOSURE STATEMENT ON A CONDITIONAL BASIS, BUT IT HAS NOT YET BEEN APPROVED BY THE BANKRUPTCY COURT Form 8 K
15/07/24	Jont Liquidation Plan and Disclosure Statement Filed by Eiger BioPharmaceuticals, Inc.
11/07/24	Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist with FDA Breakthrough Therapy Designation
10/07/24	Amylyx Pharmaceuticals Acquires Avexitide From Eiger BioPharmaceuticals for $35 Million